Century Therapeutics (IPSC) Competitors

Century Therapeutics (NASDAQ:IPSC) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.

Is IPSC or ANNX more profitable?

Annexon has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. Annexon's return on equity of -38.99% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-4,837.73%	-61.66%	-31.78%
Annexon	N/A	-38.99%	-33.90%

Does the media favor IPSC or ANNX?

In the previous week, Annexon had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 5 mentions for Annexon and 1 mentions for Century Therapeutics. Annexon's average media sentiment score of 1.30 beat Century Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, IPSC or ANNX?

Century Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Does the MarketBeat Community prefer IPSC or ANNX?

Annexon received 13 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 77.46% of users gave Annexon an outperform vote while only 70.00% of users gave Century Therapeutics an outperform vote.

Company	Underperform	Outperform
Century Therapeutics	Outperform Votes 42 70.00%	Underperform Votes 18 30.00%
Annexon	Outperform Votes 55 77.46%	Underperform Votes 16 22.54%

Do analysts prefer IPSC or ANNX?

Century Therapeutics currently has a consensus target price of $4.40, suggesting a potential upside of 709.27%. Annexon has a consensus target price of $18.67, suggesting a potential upside of 1,178.54%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Annexon	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in IPSC or ANNX?

50.2% of Century Therapeutics shares are owned by institutional investors. 6.8% of Century Therapeutics shares are owned by insiders. Comparatively, 12.7% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, IPSC or ANNX?

Annexon has lower revenue, but higher earnings than Century Therapeutics. Annexon is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$6.59M	7.10	-$136.67M	-$1.63	-0.33
Annexon	N/A	N/A	-$134.24M	-$1.02	-1.43

Summary

Annexon beats Century Therapeutics on 10 of the 16 factors compared between the two stocks.